Deep Dive: Page 6
Industry insights from our journalists
-
I/O combos inch forward in pharma's lung cancer quest
An impressive survival benefit could lift Merck's Keytruda plus chemo regimen, while Bristol-Myers hopes its checkpoint inhibitor pairing can help it catch up.
Ned Pagliarulo • April 16, 2018 -
Gene therapy heavyweights talk next steps for CAR-T
Several big names in cell and gene therapy development discussed what's on the horizon at a meeting of the Alliance for Cancer Gene Therapy.
Lisa LaMotta • April 11, 2018 -
Kendall Davis/BioPharma Dive
Abuse deterrents still finding their niche in the pain space
Hard-to-abuse opioids haven't been on the market for very long, and whether they have staying power amid a public health crisis remains an open question.
Jacob Bell • March 26, 2018 -
Courtesy of Eli Lilly
Lilly's bet on pain stands out amid bare pharma pipeline
Even as the opioid epidemic has heightened the need for non-addictive painkillers, few pharma companies have made pain a therapeutic area of focus.
Ned Pagliarulo • March 26, 2018 -
Taylor McKnight/BioPharma Dive
Incyte study could bring lessons for cancer immunotherapy
Merck has bet on the potential of Incyte's IDO blocker as a partner for Keytruda across five different cancer types. A Phase 3 trial in melanoma is first up.
Ned Pagliarulo • March 14, 2018 -
Despite crowded I/O field, pharma, VCs still eager to invest
Surging biopharma investment into cancer has raised concerns about duplicative research. Industry execs, however, see the opportunities as too great to pass up.
Ned Pagliarulo • March 9, 2018 -
For Cosentyx, Taltz, Siliq: A marketing race to differentiate
The IL-17 arena is getting pretty crowded, pushing drugmakers to explore various routes to market dominance.
Jacob Bell • March 7, 2018 -
Pharma taking liberties with DTC ads, says study
A new study analyzes current DTC ad campaigns and dissects whether disclosure of beneficial side effects could be misleading or interpreted as off-label promotion.
Randi Hernandez • March 7, 2018 -
Numbers show drugmakers are keeping RTFs under wraps
A BioPharma Dive analysis of company and FDA data show plenty of companies are not disclosing Refusal to File letters from the FDA.
Lisa LaMotta • March 5, 2018 -
Pharma moves beyond Seres hangover in microbiome space
While there have been no major acquisitions of microbiome-focused companies, early research has attracted a wealth of big pharma dollars.
Lisa LaMotta • Feb. 26, 2018 -
Cancer and the microbiome: What's old is new again
A healthy gut may improve how well cancer patients respond to immunotherapy. A big unanswered question is why.
Ned Pagliarulo • Feb. 26, 2018 -
Kendall Davis/BioPharma Dive
The (still somewhat mysterious) science behind the microbiome
Though nascent, microbiome research is offering valuable insights about how tiny organisms improve — and threaten — human health.
Jacob Bell • Feb. 26, 2018 -
Hunting for the 'good' and 'bad' bacteria in the microbiome
Research into the trillions of bacteria living in the gut has surged, boosting interest in developing diagnostics.
Suzanne Elvidge • Feb. 26, 2018 -
Courtesy of Gilead Sciences
CAR-T growing up with big pharma's big bet
Major acquisitions by Celgene and Gilead should catalyze further investment into the technology needed to make CAR-T work smoothly. Yet cell therapy's commercial potential remains an open question.
Ned Pagliarulo • Feb. 20, 2018 -
Lisa LaMotta/BioPharma Dive
Ramaswamy has no regrets about Axovant
The CEO says he wouldn't change a thing, despite the high-profile failure and sharp decline of the company.
Lisa LaMotta • Feb. 13, 2018 -
What Gilead taught pharma about pricing a cure
With Sovaldi in the rearview mirror and gene therapies progressing quickly, the industry is debating what lessons can be learned about pricing a cure.
Lisa LaMotta • Feb. 12, 2018 -
Elizabeth Regan/BioPharma Dive
Pharma wades into the world of virtual reality marketing
The technology offers drugmakers and sales reps an original way to tell stories. But whether it will hold up to the test of time remains to be seen.
Jacob Bell • Feb. 7, 2018 -
How Bristol-Myers and Pfizer are using real-world data to unseat warfarin
Eliquis, the pharmas' blood thinner, is now a blockbuster. Yet the companies see more growth ahead, tapping real-world data to convince doctors and payers.
Ned Pagliarulo • Jan. 29, 2018 -
When real-world evidence becomes a real headache
After devoting considerable time and resources to find out how a product works in everyday life, drugmakers can be left with more questions than answers.
Jacob Bell • Jan. 29, 2018 -
Elizabeth Regan/BioPharma Dive
Payers wade into real-world evidence, but tread lightly
Insurers and pharmacy benefit managers are wary about the quality of data underlying real-world evidence.
David Lim • Jan. 29, 2018 -
Industry awaits FDA on rules for real-world evidence
Top FDA officials talk up data from outside the clinic, but the agency has yet to give the industry concrete guidance for best practices.
Lisa LaMotta • Jan. 29, 2018 -
Elizabeth Regan/BioPharma Dive
Biotech CEOs: Working with CROs is challenging
Unlike their big pharma brethren, smaller biotechs don't always get preferential treatment. But most find ways to capitalize on those interactions.
Lisa LaMotta • Jan. 23, 2018 -
Elizabeth Regan/BioPharma Dive
Recent M&A: Good buys or just a stopgap?
A new slate of biotech deals has investors feeling both elated and a bit confused.
Lisa LaMotta • Jan. 23, 2018 -
Elizabeth Regan/BioPharma Dive
Price competition to hit oncology next: BioPharma Dive's 2018 predictions
Cancer drugs routinely command a premium price. A crowded pipeline of me-too rivals could change that.
Ned Pagliarulo • Jan. 10, 2018 -
Elizabeth Regan/BioPharma Dive
CNS drugs take center stage: BioPharma's 2018 predictions
Move over oncology, neuroscience is ready for the spotlight in 2018 as drugmakers delve deeper into pain and neurodegenerative disorders.
Jacob Bell • Jan. 8, 2018
Previous
